>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
BTK与PKCβ在多发性骨髓瘤中表达及调控的信号通路机制研究
作者:黄来全1  刘大翔2 
单位:1. 皖南医学院第一附属医院弋矶山医院 血液内科, 安徽 芜湖 241000;
2. 池州市人民医院 血液内科, 安徽 池州 247000
关键词:多发性骨髓瘤 Bruton酪氨酸激酶 蛋白激酶Cβ 核因子κB 
分类号:R733.3
出版年·卷·期(页码):2018·37·第四期(578-583)
摘要:

目的:分析Bruton酪氨酸激酶(BTK)与蛋白激酶Cβ(PKCβ)在多发性骨髓瘤患者肿瘤细胞(MM)和正常人骨髓血淋巴细胞中的表达,探究它们之间的调控关系以及对NF-κB的影响。方法:运用qRT-PCR和Western blotting检测BTK与PKCβ的表达情况。利用siRNA降低BTK的表达,使用抑制剂PCI-32765抑制BTK,在过表达BTK的同时抑制PKCβ,运用qRT-PCR、Western blotting检测PKCβ的变化,Western blotting检测p65核内外分布情况。结果:在30例初诊MM患者标本中,BTK的阳性率为30%,与正常人骨髓血标本相比(阳性率为5%)差异具有统计学意义;PKCβ的阳性率为46.67%,与正常人骨髓血标本相比(阳性率为15%)差异具有统计学意义。在8226细胞中降低BTK的表达或者抑制BTK后,PKCβ的mRNA和蛋白表达下调,而p65的总蛋白表达虽无变化,但是核内的p65下降。过表达BTK可使PKCβ表达上调和p65核内分布增加,但是PKCβ抑制剂LY333531可逆转BTK过表达导致的NF-κB过度激活。结论:BTK与PKCβ在多发性骨髓瘤患者的肿瘤细胞中呈高表达;BTK通过调控PKCβ激活NF-κB。

Objective:To analyze the expression of BTK and PKCβ in tumor cells of patients with multiple myeloma(MM) and normal human bone marrow lymphocytes. To explore the regulatory relationship between BTK and PKCβ and its influence on NF-kappa B. Methods:qRT-PCR and Western blotting was performed to detected the expression of BTK and PKCβ. Using the RNA interference, BTK's expression was reduced; using PCI-32765 BTK was inhibited; while overexpressing BTK in multiple myeloma cancer cells, PKCβ was inhibited. The changes of PKCβ was detected by qRT-PCR and Western blotting, and p65 nuclear distribution was detected by Western blot. Results:In 30 patients with multiple myeloma, BTK's positive rate was 30%, and compared with normal human bone marrow blood samples (positive rate was 5%), the difference was statistically significant. In addition, PKCβ's positive rate was 46.67%, compared with the normal bone marrow blood samples (positive rate was 15%), the difference was statistically significant. The expression of BTK were reduced or inhibited in human multiple myeloma cell line 8226, correspondingly, mRNA and protein expression of PKCβ were decreased. While the total protein expression of p65 did not change, p65 decreased in the nucleus. Overexpression of BTK could increase the expression of PKCβ and increase the distribution of p65 in nucleus, However, PKCβ inhibitor, LY333531, could reverse the over activation of NF-kappa B caused by overexpression of BTK. Conclusion:BTK and PKCβ are highly expressed in tumor cells of patients with multiple myeloma, BTK activates NF-kappa B by regulating PKCβ.

参考文献:

[1] BIANCHI G, ANDERSON K C. Understanding biology to tackle the disease:Multiple myeloma from bench to bedside, and back[J].CA Cancer J Clin,2014,64(6):422-444.
[2] ZHU W, CHEN W. Bortezomib-based treatment for multiple myeloma patients with renal impairment:a systematic review and meta-analysis of observational studies[J].Medicine (Baltimore),2016,95(46):e5202.
[3] GATT M E, TAKADA K, MANI M, et al. TRIM13(RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity[J].Br J Haematol,2013,162(2):210-220.
[4] PONADER S, BURGER J A. Bruton's tyrosine kinase:from x-linked agammaglobulinemia toward targeted therapy for B-cell malignancies[J].J Clin Oncol,2014,32(17):1830-1839.
[5] LUTZNY G, KOCHER T, SCHMIDT-SUPPRIAN M, et al. Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo[J].Cancer Cell,2013,23(1):77-92.
[6] 黄春妮,李山,秦雪.流式细胞术测定多发性骨髓瘤细胞表面标记的研究[J].广西医学,2007,29(7):948, 953-956.
[7] 张帅,古维立,翁杰锋.TAZ/WWTR1影响肝癌细胞SMMC-7721的侵袭、迁移能力[J].标记免疫分析与临床,2016,23(7):811-816.
[8] LUDWIG H, GREIL R, MASSZI T, et al. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma:5-year follow-up[J].Br J Haematol,2015,171(3):344-354.
[9] PALUMBO A, HAJEK R, DELFORGE M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma[J].N Engl J Med,2012,366(19):1759-1769.
[10] KENNY E F, QUINN S R, DOYLE S L, et al. Bruton's tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin[J].PLoS One,2013,8(8):e74103.
[11] MURRAY M Y, ZAITSEVA L, AUGER M J, et al.Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma[J].Cell Cycle,2015,14(14):2367-2375.
[12] SHINOHARA H, KUROSAKI T. Comprehending the complex connection between PKCbeta, TAK1, and IKK in BCR signaling[J].Immunol Rev,2009,232(1):300-318.
[13] HOESEL B, SCHMID J A. The complexity of NF-κB signaling in inflammation and cancer[J].Mol Cancer,2013,12(8):86.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 155013 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232483 83272481
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364